A citation-based method for searching scientific literature

W Brian Dalton, Patrick M Forde, Hyunseok Kang, Roisin M Connolly, Vered Stearns, Christopher D Gocke, James R Eshleman, Jennifer Axilbund, Dana Petry, Cindy Geoghegan, Antonio C Wolff, David M Loeb, Christine A Pratilas, Christian F Meyer, Eric S Christenson, Shannon A Slater, Jennifer Ensminger, Heather A Parsons, Ben H Park, Josh Lauring. JCO Precis Oncol 2017
Times Cited: 44







List of co-cited articles
252 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


OncoKB: A Precision Oncology Knowledge Base.
Debyani Chakravarty, Jianjiong Gao, Sarah M Phillips, Ritika Kundra, Hongxin Zhang, Jiaojiao Wang, Julia E Rudolph, Rona Yaeger, Tara Soumerai, Moriah H Nissan,[...]. JCO Precis Oncol 2017
960
38

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.
Christophe Massard, Stefan Michiels, Charles Ferté, Marie-Cécile Le Deley, Ludovic Lacroix, Antoine Hollebecque, Loic Verlingue, Ecaterina Ileana, Silvia Rosellini, Samy Ammari,[...]. Cancer Discov 2017
360
31

Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists.
Marilyn M Li, Michael Datto, Eric J Duncavage, Shashikant Kulkarni, Neal I Lindeman, Somak Roy, Apostolia M Tsimberidou, Cindy L Vnencak-Jones, Daynna J Wolff, Anas Younes,[...]. J Mol Diagn 2017
773
31

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalves, Céline Gavoille, Coraline Dubot, Nicolas Isambert, Mario Campone, Olivier Trédan, Marie-Ange Massiani, Cécile Mauborgne,[...]. Lancet Oncol 2015
641
31

Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin,[...]. Nat Med 2017
29

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, N Lopez-Bigas, C K Y Ng, P L Bedard, G Tortora, J-Y Douillard,[...]. Ann Oncol 2018
203
27

Implementation of a Molecular Tumor Board: The Impact on Treatment Decisions for 35 Patients Evaluated at Dartmouth-Hitchcock Medical Center.
Laura J Tafe, Ivan P Gorlov, Francine B de Abreu, Joel A Lefferts, Xiaoying Liu, Jason R Pettus, Jonathan D Marotti, Kasia J Bloch, Vincent A Memoli, Arief A Suriawinata,[...]. Oncologist 2015
62
25

Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
Clémence Basse, Claire Morel, Marie Alt, Marie Paule Sablin, Coralie Franck, Gaëlle Pierron, Céline Callens, Samia Melaabi, Julien Masliah-Planchon, Guillaume Bataillon,[...]. ESMO Open 2018
25
44

Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Tracy L Stockley, Amit M Oza, Hal K Berman, Natasha B Leighl, Jennifer J Knox, Frances A Shepherd, Eric X Chen, Monika K Krzyzanowska, Neesha Dhani, Anthony M Joshua,[...]. Genome Med 2016
148
25

Molecular tumor board: the University of California-San Diego Moores Cancer Center experience.
Maria Schwaederle, Barbara A Parker, Richard B Schwab, Paul T Fanta, Sarah G Boles, Gregory A Daniels, Lyudmila A Bazhenova, Rupa Subramanian, Alice C Coutinho, Haydee Ojeda-Fournier,[...]. Oncologist 2014
119
22

Clinical benefit of a precision medicine based approach for guiding treatment of refractory cancers.
Milan Radovich, Patrick J Kiel, Stacy M Nance, Erin E Niland, Megan E Parsley, Meagan E Ferguson, Guanglong Jiang, Natraj R Ammakkanavar, Lawrence H Einhorn, Liang Cheng,[...]. Oncotarget 2016
57
22

Implementation and utilization of the molecular tumor board to guide precision medicine.
Shuko Harada, Rebecca Arend, Qian Dai, Jessica A Levesque, Thomas S Winokur, Rongjun Guo, Martin J Heslin, Lisle Nabell, L Burt Nabors, Nita A Limdi,[...]. Oncotarget 2017
43
23

Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial.
O Trédan, Q Wang, D Pissaloux, P Cassier, A de la Fouchardière, J Fayette, F Desseigne, I Ray-Coquard, C de la Fouchardière, D Frappaz,[...]. Ann Oncol 2019
80
22

Rationale and Design of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
Pam K Mangat, Susan Halabi, Suanna S Bruinooge, Elizabeth Garrett-Mayer, Ajjai Alva, Katherine A Janeway, Philip J Stella, Emile Voest, Kathleen J Yost, Jane Perlmutter,[...]. JCO Precis Oncol 2018
66
22

Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience.
Todd C Knepper, Gillian C Bell, J Kevin Hicks, Eric Padron, Jamie K Teer, Teresa T Vo, Nancy K Gillis, Neil T Mason, Howard L McLeod, Christine M Walko. Oncologist 2017
46
20

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.
Jason K Sicklick, Shumei Kato, Ryosuke Okamura, Maria Schwaederle, Michael E Hahn, Casey B Williams, Pradip De, Amy Krie, David E Piccioni, Vincent A Miller,[...]. Nat Med 2019
257
18

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
15

Precision oncology based on omics data: The NCT Heidelberg experience.
Peter Horak, Barbara Klink, Christoph Heining, Stefan Gröschel, Barbara Hutter, Martina Fröhlich, Sebastian Uhrig, Daniel Hübschmann, Matthias Schlesner, Roland Eils,[...]. Int J Cancer 2017
86
15

Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
Maria Schwaederle, Melissa Zhao, J Jack Lee, Alexander M Eggermont, Richard L Schilsky, John Mendelsohn, Vladimir Lazar, Razelle Kurzrock. J Clin Oncol 2015
268
15

Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery.
Alan H Bryce, Jan B Egan, Mitesh J Borad, A Keith Stewart, Grzegorz S Nowakowski, Asher Chanan-Khan, Mrinal M Patnaik, Stephen M Ansell, Michaela S Banck, Steven I Robinson,[...]. Oncotarget 2017
38
18

Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
Garrett M Frampton, Alex Fichtenholtz, Geoff A Otto, Kai Wang, Sean R Downing, Jie He, Michael Schnall-Levin, Jared White, Eric M Sanford, Peter An,[...]. Nat Biotechnol 2013
15

Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial.
Jordi Rodon, Jean-Charles Soria, Raanan Berger, Wilson H Miller, Eitan Rubin, Aleksandra Kugel, Apostolia Tsimberidou, Pierre Saintigny, Aliza Ackerstein, Irene Braña,[...]. Nat Med 2019
208
15

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Daniel D Von Hoff, Joseph J Stephenson, Peter Rosen, David M Loesch, Mitesh J Borad, Stephen Anthony, Gayle Jameson, Susan Brown, Nina Cantafio, Donald A Richards,[...]. J Clin Oncol 2010
432
15

A virtual molecular tumor board to improve efficiency and scalability of delivering precision oncology to physicians and their patients.
Michael J Pishvaian, Edik M Blais, R Joseph Bender, Shruti Rao, Simina M Boca, Vincent Chung, Andrew E Hendifar, Sam Mikhail, Davendra P S Sohal, Paula R Pohlmann,[...]. JAMIA Open 2019
29
24

The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs.
D L van der Velden, L R Hoes, H van der Wijngaart, J M van Berge Henegouwen, E van Werkhoven, P Roepman, R L Schilsky, W W J de Leng, A D R Huitema, B Nuijen,[...]. Nature 2019
87
15

CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer.
Malachi Griffith, Nicholas C Spies, Kilannin Krysiak, Joshua F McMichael, Adam C Coffman, Arpad M Danos, Benjamin J Ainscough, Cody A Ramirez, Damian T Rieke, Lynzey Kujan,[...]. Nat Genet 2017
284
13

Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative.
Apostolia-Maria Tsimberidou, Nancy G Iskander, David S Hong, Jennifer J Wheler, Gerald S Falchook, Siqing Fu, Sarina Piha-Paul, Aung Naing, Filip Janku, Rajyalakshmi Luthra,[...]. Clin Cancer Res 2012
375
13

Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.
David M Hyman, Igor Puzanov, Vivek Subbiah, Jason E Faris, Ian Chau, Jean-Yves Blay, Jürgen Wolf, Noopur S Raje, Eli L Diamond, Antoine Hollebecque,[...]. N Engl J Med 2015
13

Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Jennifer J Wheler, Filip Janku, Aung Naing, Yali Li, Bettzy Stephen, Ralph Zinner, Vivek Subbiah, Siqing Fu, Daniel Karp, Gerald S Falchook,[...]. Cancer Res 2016
157
13

Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.
John D Hainsworth, Funda Meric-Bernstam, Charles Swanton, Herbert Hurwitz, David R Spigel, Christopher Sweeney, Howard Burris, Ron Bose, Bongin Yoo, Alisha Stein,[...]. J Clin Oncol 2018
251
13

Personalized Clinical Decision Making Through Implementation of a Molecular Tumor Board: A German Single-Center Experience.
Rouven Hoefflin, Anna-Lena Geißler, Ralph Fritsch, Rainer Claus, Julius Wehrle, Patrick Metzger, Meike Reiser, Leman Mehmed, Lisa Fauth, Dieter Henrik Heiland,[...]. JCO Precis Oncol 2018
23
26

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Kathleen Moore, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Ana Oaknin, Michael Friedlander, Alla Lisyanskaya, Anne Floquet, Alexandra Leary, Gabe S Sonke,[...]. N Engl J Med 2018
11

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Mark Robson, Seock-Ah Im, Elżbieta Senkus, Binghe Xu, Susan M Domchek, Norikazu Masuda, Suzette Delaloge, Wei Li, Nadine Tung, Anne Armstrong,[...]. N Engl J Med 2017
11

Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.
Sue Richards, Nazneen Aziz, Sherri Bale, David Bick, Soma Das, Julie Gastier-Foster, Wayne W Grody, Madhuri Hegde, Elaine Lyon, Elaine Spector,[...]. Genet Med 2015
11

Molecular Tumor Boards: current practice and future needs.
D L van der Velden, C M L van Herpen, H W M van Laarhoven, E F Smit, H J M Groen, S M Willems, P M Nederlof, M H G Langenberg, E Cuppen, S Sleijfer,[...]. Ann Oncol 2017
66
11

Prospective analysis of 895 patients on a UK Genomics Review Board.
David Allan Moore, Marina Kushnir, Gabriel Mak, Helen Winter, Teresa Curiel, Mark Voskoboynik, Michele Moschetta, Nataliya Rozumna-Martynyuk, Kevin Balbi, Philip Bennett,[...]. ESMO Open 2019
16
31

Implementation and Clinical Utility of an Integrated Academic-Community Regional Molecular Tumor Board.
Mark E Burkard, Dustin A Deming, Benjamin M Parsons, Paraic A Kenny, Marissa R Schuh, Ticiana Leal, Nataliya Uboha, Joshua M Lang, Michael A Thompson, Ruth Warren,[...]. JCO Precis Oncol 2017
11
45

Variant classification in precision oncology.
Jonas Leichsenring, Peter Horak, Simon Kreutzfeldt, Christoph Heining, Petros Christopoulos, Anna-Lena Volckmar, Olaf Neumann, Martina Kirchner, Carolin Ploeger, Jan Budczies,[...]. Int J Cancer 2019
34
14

Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.
Kim M Hirshfield, Denis Tolkunov, Hua Zhong, Siraj M Ali, Mark N Stein, Susan Murphy, Hetal Vig, Alexei Vazquez, John Glod, Rebecca A Moss,[...]. Oncologist 2016
45
11

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
Talia Golan, Pascal Hammel, Michele Reni, Eric Van Cutsem, Teresa Macarulla, Michael J Hall, Joon-Oh Park, Daniel Hochhauser, Dirk Arnold, Do-Youn Oh,[...]. N Engl J Med 2019
897
11

Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer.
Christian Rolfo, Paolo Manca, Roberto Salgado, Peter Van Dam, Amelie Dendooven, Jose Ferri Gandia, Annemie Rutten, Willem Lybaert, Joanna Vermeij, Thomas Gevaert,[...]. ESMO Open 2018
49
11

Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Funda Meric-Bernstam, Lauren Brusco, Kenna Shaw, Chacha Horombe, Scott Kopetz, Michael A Davies, Mark Routbort, Sarina A Piha-Paul, Filip Janku, Naoto Ueno,[...]. J Clin Oncol 2015
294
11

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
9

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
9

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
9

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
9

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.
Paul B Chapman, Axel Hauschild, Caroline Robert, John B Haanen, Paolo Ascierto, James Larkin, Reinhard Dummer, Claus Garbe, Alessandro Testori, Michele Maio,[...]. N Engl J Med 2011
9

A decision support framework for genomically informed investigational cancer therapy.
Funda Meric-Bernstam, Amber Johnson, Vijaykumar Holla, Ann Marie Bailey, Lauren Brusco, Ken Chen, Mark Routbort, Keyur P Patel, Jia Zeng, Scott Kopetz,[...]. J Natl Cancer Inst 2015
133
9

Physicians' attitudes about multiplex tumor genomic testing.
Stacy W Gray, Katherine Hicks-Courant, Angel Cronin, Barrett J Rollins, Jane C Weeks. J Clin Oncol 2014
155
9

The clinical impact of using complex molecular profiling strategies in routine oncology practice.
Jean-François Laes, Philippe Aftimos, Philippe Barthelemy, Joaquim Bellmunt, Guy Berchem, Carlos Camps, Ramón de Las Peñas, Ana Finzel, Jesús García-Foncillas, Petteri Hervonen,[...]. Oncotarget 2018
11
36


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.